Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

The Management of HCC: Moving Forward

November 28th 2018

Emerging Novel Combinations in Advanced HCC

November 28th 2018

Opportunities for Checkpoint Inhibitors in Advanced HCC

November 28th 2018

Considerations for Using Nivolumab in Advanced HCC

November 28th 2018

Ramucirumab After Progression in Advanced HCC

November 28th 2018

Sequencing With Cabozantinib in Advanced HCC

November 28th 2018

Regorafenib Following First-Line Systemic Therapy in HCC

November 28th 2018

Lenvatinib As Up-front Therapy for Unresectable HCC

November 28th 2018

Sorafenib Initiation After TACE in HCC

November 28th 2018

Prognostic and Predictive Markers in HCC

November 28th 2018

Radiotherapy Use in HCC

November 28th 2018

Locoregional Therapy in HCC: Additional Considerations

November 28th 2018

Combining TACE With Systemic Therapy in Advanced HCC

November 28th 2018

Global Perspective on Locoregional Therapies in HCC

November 28th 2018

Treatment Strategies for Early-Stage HCC

November 28th 2018

Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic Cancer

November 28th 2018

Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.

Combos Pairing Inhibitors of Angiogenesis and Immune Checkpoints Have Potential

November 25th 2018

Therapies that inhibit angiogenesis are attracting fresh interest in combination regimens with immune checkpoint immunotherapy in tumor types such as hepatocellular carcinoma, urothelial carcinoma, and endothelial cancer.

Tumor Mutational Burden in CRC

November 21st 2018

Efficacy and Safety of Immunotherapy for mCRC

November 21st 2018

TAS-102 Versus Regorafenib for Treating mCRC

November 21st 2018